Palak Shah
Advanced Heart Failure and Transplant Cardiology · Falls Church, VANPI 1336313717
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $93,893 of the $112,032 with a category attached, or 83.8%. 18 manufacturers reported payments, led by Merck at 59.1% of the total. Reporting peaked in 2023 at $37,560 and has fallen 91.8% since, to $3,065 in 2025. Among advanced heart failure and transplant cardiology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 114 payments — averaging $982.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$66K
- Procyrion, Inc.$37K
- Roche Diagnostics Corporation$6K
- Abbott$2K
- Abiomed$323
- Cvrx, Inc.$201
- plus $350 from 12 others
Across 49 payments — averaging $12,266 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$276K
- Roche Diagnostics Corporation$110K
- Merck$97K
- Ortho-clinical Diagnostics, Inc.$50K
- AstraZeneca$34K
- Briohealth Solutions, Inc.$21K
- plus $13K from 2 others
What the payments were for
- Consulting fees$93,89384%
- Travel & lodging$13,51212%
- Food & beverage$4,6274%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 55 | $66,196 |
| Procyrion, Inc. | 4 | $37,112 |
| Roche Diagnostics Corporation | 7 | $5,553 |
| Abbott | 27 | $2,296 |
| Abiomed | 6 | $323 |
| Cvrx, Inc. | 2 | $201 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $43 |
| Supreme Orthopedic Systems, LLC | 1 | $41 |
| Lexicon Pharmaceuticals, Inc. | 1 | $35 |
| Sanara Medtech Inc. | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Briohealth Solutions, Inc. | 1 | $27 |
| United Therapeutics Corporation | 1 | $26 |
| Novartis | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $24 |
| Medtronic | 1 | $23 |
| Incyte Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$46,634
- AORTIX SYSTEM$37,100
- CD cobas Reagents$5,445
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,372
- MK-1242$486
- HeartMate$232
- AMPLATZER TALISMAN$176
- Impella$159
- Barostim Neo System$152
How this compares
$112,032 in reported general payments places this provider in the 90th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 49 | $64,600 |
| JardianceEmpagliflozin | 28 | $43,173 |
| EliquisApixaban | 26 | $26,814 |
| Metoprolol Succinate | 26 | $699 |
| Bumetanide | 11 | $557 |
| Rosuvastatin Calcium | 21 | $516 |
| Digoxin | 18 | $501 |
| Potassium Chloride | 11 | $415 |
| Warfarin Sodium | 30 | $398 |
| Carvedilol | 32 | $299 |
| Spironolactone | 34 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $24 | $64,60049 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
Other advanced heart failure and transplant cardiology in Falls Church
- Shashank DesaiFalls Church$80K
- Michael FlanaganFalls Church$29K
- Lauren CooperFalls Church$21K
- Allman RollinsFalls Church$9K
- Iyad IssehFalls Church$6K
- Jamie KennedyFalls Church$4K
- Timothy WelchFalls Church$4K
- Lena AliFalls Church$2K
- Vanessa BlumerFalls Church$2K
- Amin YehyaNorfolk$398K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.